The ICORG 08-02 Nilotinib study has reached its target accrual of 60 patients in May 2011. The last 8 patients were accrued within 8 weeks, just making the mid-May deadline. As a result of this great study teamwork and effort we are able to report on the primary objective for all 60 patients. Upon study completion an abstract has been recently submitted to a top U.S. meeting (American Society of Hematology (ASH)) and we are hopeful that it will be accepted as an oral presentation at the next ASH meeting in December 2011.
Cancer Trials Ireland > news import > Uncategorised > Nilotinib Leukemia Trial ICORG number 08-02 Completes Accrual